"Interferon-alpha" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells. In addition to antiviral activity, it activates NATURAL KILLER CELLS and B-LYMPHOCYTES, and down-regulates VASCULAR ENDOTHELIAL GROWTH FACTOR expression through PI-3 KINASE and MAPK KINASES signaling pathways.
| Descriptor ID |
D016898
|
| MeSH Number(s) |
D12.644.276.374.440.890.250 D12.776.467.374.440.890.250 D23.529.374.440.890.250
|
| Concept/Terms |
Interferon-alpha- Interferon-alpha
- Interferon alpha
- alpha-Interferon
- alpha Interferon
- Interferon, Lymphoblastoid
- Lymphoblastoid Interferon
- Interferon, Lymphoblast
- Lymphoblast Interferon
- Interferon Alfa
- Interferon, alpha
- Interferon, Leukocyte
- Leukocyte Interferon
Interferon alpha-17- Interferon alpha-17
- Interferon alpha 17
- Interferon alpha-T
- Interferon alpha T
- LeIF I
- Interferon alpha-88
- Interferon alpha 88
Interferon alpha-7- Interferon alpha-7
- Interferon alpha 7
- LeIF J
- Interferon alpha-J
- Interferon alpha J
Interferon alpha-5- Interferon alpha-5
- Interferon alpha 5
- Interferon alpha5
- IFN-alpha5
- IFN alpha5
Interferon alpha-2- Interferon alpha-2
- Interferon alpha 2
- Interferon-alpha 2
- Interferon alpha-A
- Interferon alpha A
- LeIF A
- IFN-alpha 2
- IFN-alpha-2
|
Below are MeSH descriptors whose meaning is more general than "Interferon-alpha".
Below are MeSH descriptors whose meaning is more specific than "Interferon-alpha".
This graph shows the total number of publications written about "Interferon-alpha" by people in this website by year, and whether "Interferon-alpha" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1998 | 1 | 1 | 2 |
| 2000 | 0 | 2 | 2 |
| 2001 | 1 | 1 | 2 |
| 2002 | 1 | 2 | 3 |
| 2003 | 1 | 1 | 2 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 2 | 2 | 4 |
| 2008 | 4 | 2 | 6 |
| 2009 | 3 | 1 | 4 |
| 2010 | 2 | 5 | 7 |
| 2011 | 4 | 2 | 6 |
| 2012 | 4 | 2 | 6 |
| 2013 | 1 | 0 | 1 |
| 2014 | 2 | 0 | 2 |
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 1 | 2 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Interferon-alpha" by people in Profiles.
-
Type 1 interferon to prevent leukemia relapse after allogeneic transplantation. Blood Adv. 2021 12 14; 5(23):5047-5056.
-
Individual liver plasmacytoid dendritic cells are capable of producing IFNa and multiple additional cytokines during chronic HCV infection. PLoS Pathog. 2019 07; 15(7):e1007935.
-
An Interferon-Induced Digital Vasculitis-Like Syndrome: A Case Report. Am J Ther. 2016 May-Jun; 23(3):e920-5.
-
Faldaprevir, pegylated interferon, and ribavirin for treatment-na?ve HCV genotype-1: pooled analysis of two phase 3 trials. Ann Hepatol. 2016 May-Jun; 15(3):333-49.
-
Anti-cytokine autoantibodies in postherpetic neuralgia. J Transl Med. 2015 Oct 20; 13:333.
-
Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C. Liver Int. 2015 Jan; 35 Suppl 1:11-7.
-
Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin. J Hepatol. 2015 Feb; 62(2):294-302.
-
Serum free light chains, interferon-alpha, and interleukins in systemic lupus erythematosus. Lupus. 2014 Aug; 23(9):881-8.
-
Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatment. J Clin Gastroenterol. 2013 Oct; 47(9):786-93.
-
Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies. Expert Opin Drug Saf. 2012 Nov; 11(6):901-9.